BED-PSMA-301: PET for Prostate Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about the safety and performance of a radioactive tracer agent called rhPSMA-7.3 (18F) in Positron Emission Tomography (PET) imaging for prostate cancer.

What is the Condition Being Studied?

Prostate Cancer

Who Can Participate in the Study?

Men, 18+ who:
- Have intermediate-risk prostate cancer
- Are candidates for radical prostatectomy with pelvic lymph node dissection
- Do not have any other health conditions that may risk your ability to participate in the study

Age Group

What is Involved?

If you choose to join this study, you will:
-Complete 3 study visits
-Have blood tests and physical exams
-Have the study agent (rhPSMA-7.3) given
-Have a research PET imaging scan
-Complete follow-up evaluations

Study Details

Full Title
A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer
Principal Investigator
Surgical Oncologist
Protocol Number
IRB: PRO00105041
NCT: NCT04186819
Phase III
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center